SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the activation of Brooke Army Medical Center (BAMC) and the United States Army Institute of Surgical Research (USAISR), expanding the number of sites in its NEUTRALIZE-AKI pivotal trial. This trial is evaluating the safety and efficacy of SeaStar Medical’s innovative Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in adult ICU patients receiving continuous kidney replacement therapy (CKRT). With the inclusion of these prestigious military medical facilities, SeaStar Medical now has 11 active clinical sites with 48 subjects enrolled to date.

Read more at globenewswire.com